

ASX Announcement (ASX: HLS)

ASX Limited
Market Announcements Office
Exchange Centre
Level 4, 20 Bridge Street
Sydney NSW 2000



ACN 064 530 516
REGISTERED OFFICE:
LEVEL 22
161 Castlereagh Street
SYDNEY NSW 2000
TEL: +61 2 9432 9400
FAX: +61 2 9432 9447

1 May 2023

Healius updates on ASX waiver for issue of performance rights

Healius Limited (“Healius”) (ASX:HLS) today announced that the ASX has granted Healius a waiver from Listing Rule 7.9 to allow Healius to issue up to 3,005,603 performance rights as part of its FY 2023 grant under the Healius Long Term Incentive Plan (LTIP).

At Healius’ Annual General Meeting on 20 October 2022 Healius shareholders approved the issue of up to 12,000,000 performance rights under the LTIP for a period of three years in accordance with Listing Rule 7.2 exception 13. Healius has made regular annual grants of performance rights under its incentive plans for many years.

The Company was finalising the details of the FY 2023 grant of performance rights under the LTIP in the days immediately preceding 20 March 2023, on which date Australian Clinical Labs Limited notified Healius it was making a takeover bid for all of the issued shares of Healius.

Listing Rule 7.9 prevents an entity from issuing securities within three months of being notified in writing that a person is making a takeover bid for securities in it. This waiver will enable Healius to issue up to 3,005,603 performance rights as part of its FY 2023 LTIP.

The number of securities to be issued is de minimis in the context of the overall issued share capital (representing 0.53% of its current share capital).

ENDS

The release of this announcement has been authorised by the Chair.

For further information contact:

Analysts and Market

Janet Payne
Group Executive, Corporate Affairs
Mobile: +61 409 995 517

Media

Andrew Butcher
Bespoke Approach
Mobile: +61 400 841 088

Shareholders

Computershare Investor Centre
Phone: 1300 850 505
<https://www.computershare.com/au>

For over 30 years Healius has been one of Australia’s leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Today, Healius has two core diagnostics businesses, pathology and imaging. Through its unique footprint of centres and its 10,500 employees, Healius provides Australia-wide specialty diagnostic services to consumers and their referring practitioners.